Short-read sequencing

Illumina’s short-read sequencing-by-synthesis is the gold standard for scientific research worldwide.

Next-generation sequencing platforms still represent a significant investment for individual research laboratories and require a great deal of technical expertise and time to maintain. As a dedicated centre running both the high output NovaSeq X Plus and low output MiSeq i100 short read platforms, the CGR enables researchers to access the best platform for their specific project, while ensuring maximum return on their investment.

An image of a Novaseq X Plus high-throughput DNA sequencer.

The NovaSeq X Plus is a high-throughput platform launched by Illumina in 2023. It provides the CGR with the speed and flexibility to complete projects quicker and more economically than ever before. Applications requiring large amounts of high-quality sequence data, such as human whole-genome sequencing, cannot be completed in a more cost-effective manner.

Introduction to MiSeq™ i100 Series: Empowering every lab, everywhere

The CGR acquired the Illumina MiSeq i100 Plus in late 2025 to replace our previous Illumina MiSeq benchtop system. It is a next-generation platform designed for rapid, high-quality sequencing of small-scale projects. With faster run times and a streamlined workflow, it enables quicker turnaround and more efficient processing of small projects, making it ideal for sequencing amplicons, microbial genomes, and targeted panels. The platform supports high-precision variant detection, delivering reliable results with excellent reproducibility across a range of research applications.